DIA
NBIX icon

Dana Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Dana Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,005
Closed -$254K – 278
2019
Q2 		$254K Buy
+3,005
New +$247K 0.01% 265

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dana Investment Advisors's NBIX Position: Q3 2019 in Review

Dana Investment Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2019, closing a stake of 3,005 shares — an estimated $254K sold.

Dana Investment Advisors first reported a position in NBIX in Q2 2019 and held it in 1 quarter. The position peaked at $254K in Q2 2019. 332 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Dana Investment Advisors reported no remaining Neurocrine Biosciences position as of Q3 2019 after selling out during the quarter.
  • Dana Investment Advisors sold 3,005 Neurocrine Biosciences shares in Q3 2019, an estimated $254K.
  • Dana Investment Advisors first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 1 quarter.
  • Dana Investment Advisors's Neurocrine Biosciences position peaked at $254K in Q2 2019.
  • 332 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Dana Investment Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.